Dual-target CAR-NK therapy for advanced HER2-positive and triple-negative breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This two-part, first-in-program trial gives adults with advanced HER2-positive or triple-negative breast cancer a biomarker-guided, dual-target CAR-NK cell therapy after short-course lymphodepleting chemotherapy. Tumor samples are tested for HER2, MUC1, and ROR1 (and mesothelin in some TNBC cases) to select one of three CAR-NK products matched to each patient’s dominant antigen profile. Part A uses dose escalation to identify a safe and feasible dose, and Part B enrolls biomarker-defined expansion cohorts to look for preliminary anti-tumor activity. The allogeneic, cryopreserved NK product is engineered with a dual-specific CAR and an inducible safety switch and is administered intravenously.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed breast carcinoma that is locally advanced, unresectable, or metastatic.
* Disease subtype: HER2-positive breast cancer or triple-negative breast cancer (TNBC).
* Progression after, intolerance to, or ineligibility for standard therapies appropriate for the disease subtype and line of therapy.
* At least one measurable lesion per RECIST v1.1.
* Tumor antigen assessment available (fresh or archival): expression of at least one candidate target antigen (HER2/ERBB2, MUC1, or ROR1). For TNBC, mesothelin assessment may be performed for exploratory analyses.
* ECOG performance status 0-1.
* Adequate organ function (example thresholds): ANC ≥ 1.0 x 10\^9/L; platelets ≥ 75 x 10\^9/L; hemoglobin

  * 8 g/dL; AST/ALT ≤ 3x ULN (≤ 5x with liver metastases); total bilirubin ≤ 1.5x ULN; creatinine clearance
  * 50 mL/min.
* Left ventricular ejection fraction (LVEF) ≥ 45% and no uncontrolled cardiac arrhythmia.
* Negative pregnancy test for participants of childbearing potential; agreement to use effective contraception during study treatment and for 6 months after last CAR-NK infusion.
* Ability to understand and willingness to sign informed consent.

Exclusion Criteria:

* Active, untreated central nervous system (CNS) metastases or leptomeningeal disease. Patients with treated CNS metastases may be eligible if clinically stable for ≥ 4 weeks and off high-dose steroids.
* Prior gene-modified cellular therapy (e.g., CAR-T or CAR-NK) within 6 months or unresolved grade ≥ 2 toxicity from prior cellular therapy.
* Clinically significant active autoimmune disease requiring systemic immunosuppression (physiologic steroid replacement permitted).
* Uncontrolled infection, including uncontrolled HBV, HCV, or HIV infection (controlled infections may be eligible per investigator).
* History of severe hypersensitivity to fludarabine or cyclophosphamide.
* Pregnant or breastfeeding.
* Concurrent participation in another interventional study that could confound safety or efficacy assessments.
* Any condition that, in the investigator's judgment, would make the participant unsuitable for the study (e.g., uncontrolled comorbidity, inability to comply with protocol procedures).

Where it's running

• Peking University Shenzhen Hospital
  Shenzhen, Guangdong, China Recruiting

Study contacts

• Study coordinator: shan S Lu, Phd
• Email: Seni-Lu@beijing-biotech.com
• Phone: +86 13076790030

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using MRI to detect early breast cancer metastases

  This study is testing if a special type of MRI can help find early signs of breast cancer returning in high-risk patients to see if it can improve their chances of living longer.

  Recruiting European Institute of Oncology · Milan · NCT06328465

• Non-surgical treatment for breast cancer after chemotherapy

  This study tests if using radiotherapy alone is a safe and effective option for breast cancer patients who have responded well to chemotherapy, instead of undergoing surgery.

  Recruiting European Institute of Oncology · Candiolo, Turin and 1 other locations · NCT06281210

• Using advanced mammography techniques to assess breast cancer treatment response

  This study is testing two new mammography techniques to see if they can better predict how well chemotherapy is working for people with locally advanced breast cancer.

  Recruiting Early Phase 1 Stony Brook University · Stony Brook, New York · NCT06220214

• Investigating ctDNA in Breast Cancer Treatment

  This study is testing if blood samples can help predict how well neoadjuvant chemotherapy works for women with stage II-III HER2-positive and triple-negative breast cancer.

  Recruiting at 3 sites Gene Solutions · Jakarta and 2 other locations · NCT06087120

• Platform program for evaluating treatments in metastatic HER2-positive breast cancer

  This study is testing different new treatments for people with advanced HER2-positive breast cancer to see which ones work best before moving them to larger trials.

  Recruiting at 5 sites Phase 1/2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 9 other locations · NCT05868226

• Screening brain MRIs for patients with stage IV breast cancer

  This study tests if regular brain MRI scans can help find hidden issues in the brains of patients with stage IV breast cancer who don’t have any symptoms yet.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Clearwater, Florida and 1 other locations · NCT05115474

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.